Precigen, Inc. (PGEN) - Q2 2024 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2024. Precigen, Inc. is a clinical-stage biopharmaceutical company focused on gene and cell therapies. The company operates two primary segments: Biopharmaceuticals (including the recently suspended ActoBio subsidiary) and Exemplar (preclinical research models). In August 2024, management announced a strategic prioritization to focus resources on the lead program PRGN-2012, resulting in the shutdown of ActoBio operations and a reduction of over 20% of the workforce.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Total Revenues | $0.72 million | $1.77 million | $1.78 million | $3.62 million |
| Net Loss | $(58.79) million | $(20.32) million | $(82.53) million | $(43.05) million |
| Operating Loss | $(60.84) million | $(21.12) million | $(85.25) million | $(44.60) million |
| Cash & Short-Term Investments | $19.54 million (as of June 30, 2024) | |||
| Net Cash Used in Operating Activities | N/A | $(37.20) million | $(34.16) million | |
| Debt | No outstanding balance on revolving line of credit; Convertible Notes retired in 2023. |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 59.4% year-over-year for Q2 2024, driven primarily by reduced service volumes at the Exemplar segment.
- Significant Impairment Charges: The company recorded $34.5 million in non-cash impairment charges in Q2 2024 related to the suspension of ActoBio operations. This includes $1.63 million in goodwill impairment and $32.92 million in impairment of other noncurrent assets (intangible assets, property, plant, and equipment).
- Increased Operating Expenses: Operating expenses surged 169% year-over-year to $61.6 million, largely due to the aforementioned impairment charges and severance costs ($2.1 million) associated with the ActoBio shutdown.
- Segment Performance: Biopharmaceuticals Segment Adjusted EBITDA loss widened to $(27.6) million from $(17.3) million. Exemplar Segment Adjusted EBITDA turned negative at $(0.5) million compared to a loss of $(0.1) million in the prior year.
Guidance, Outlook, and Risks
- Strategic Pivot: Management is streamlining resources to focus on the commercialization of PRGN-2012 (AdenoVerse gene therapy for RRP). A rolling Biologics License Application (BLA) is anticipated in the second half of 2024, with a potential launch in 2025.
- Program Pauses: Clinical trials for PRGN-3005 and PRGN-3007 (UltraCAR-T) and preclinical programs have been paused. Enrollment in the PRGN-2009 cervical cancer trial at non-NCI sites will also be paused.
- Liquidity and Going Concern: The filing states there is substantial doubt about the company's ability to continue as a going concern. While the company raised approximately $31.4 million in net proceeds from a public offering in August 2024, management projects these funds, combined with cost reductions, will only support operations into early 2025. Additional capital will be required.
- Future Costs: The company expects to record an additional $0.9 million in severance charges in Q3 2024 related to the workforce reduction.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $19.5 million cash balance plus the $31.4 million August 2024 proceeds against the projected burn rate to confirm the "early 2025" liquidity timeline.
- PRGN-2012 Timeline: Monitor the status of the rolling BLA submission and FDA interactions for the accelerated approval pathway.
- Asset Monetization: Track progress on potential transactions or partnerships for the ActoBio intellectual property portfolio following the operational shutdown.
- Further Dilution: Assess the likelihood and terms of future equity or debt financings required to fund operations beyond early 2025.
- Severance Execution: Confirm the timing and total cost of the remaining workforce reduction and associated severance payments.